^
Association details:
| Biomarker: | RAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Excerpt:
...- Able to provide a sufficient amount of representative tumor specimen for central laboratory testing of RAS mutation status and microsatellite stable (MSS)....
Trial ID:
Source:
Title:
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Excerpt:
...- Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or MEK at a CLIA certified laboratory...
Trial ID:
More C2 evidence
Source:
Title:
RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer. RASTRIC-studie: onderzoek naar de veiligheid en effectiviteit van een nieuwe behandeling met drie middelen voor RAS-gemuteerde uitgezaaide dikke darmkanker.
Excerpt:
...Written documentation of a known pathogenic RAS mutation.4. ...
Trial ID:
Less C2 evidence
Source:
Title:
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Published date:
10/16/2023
Excerpt:
Pts >18 years with RAS mt mCRC, ECOG 0-1, acceptable organ function, measurable disease, and progression or ineligibility to oxaliplatin. Pts received binimetinib plus mFOLFIRI...Of the 25 pts, 24 were evaluable for response. Best response included 1 PR and 12 SD (all had received prior irinotecan and 10 had progressed on it). 4 pts remained on study for >6 months (7-15). The median PFS was 3.35 months (95% CI 2-8.61) and the median OS was 8.41 months (95% CI 4.7-12.8)....MEKi plus mFOLFIRI has acceptable toxicity and showed activity even in patients with prior progression on irinotecan.
Secondary therapy:
FOLFIRI
